United States: State Pharmaceutical Pricing Disclosure Laws: Old Story, New Refrain

Last Updated: August 27 2015
Article by Ellyn Sternfield

As a veteran of the AWP litigation era, I am struck by the recent state efforts to legislate transparency into pharmaceutical pricing. Multiple states have introduced bills that would require pharmaceutical manufacturers to produce information to justify the sales price for their drugs. But the idea that pharmaceutical manufacturers are unilaterally responsible for the costs borne by citizens of these states ignores the tangled web of policies and processes that makes up drug pricing and reimbursement in the United States. State legislators may want to examine the relatively recent history of state Average Wholesale Price (AWP) litigation, and each of their state's response to the pricing transparency mandates incorporated into the early AWP case settlements, before moving forward to mandate transparency from just one player in the process.

State Legislative Efforts to Impose Manufacturer Disclosure Requirements

California, Massachusetts, New York, North Carolina, Oregon, and Pennsylvania are among the states considering legislation requiring drug manufacturers to disclose specified information related to the costs of their drugs. The proposals are not uniform as to when disclosure is required, what is to be disclosed, and to whom the information is to be disclosed. For example:

  • The North Caroline bill applies to seven specified types of brand medicines, including biologics; the New York, Oregon and California bills apply to drugs with a Wholesale Acquisition Cost of over $10,000/year; and, the Massachusetts bill applies to drugs the Office of Statewide Health Planning & Development labels as "critical" based on vague criteria.
  • Most of the bills require the manufacturers to disclose the Wholesale Acquisition Cost (WAC) of the drugs; WAC is defined in federal law. The NC bill requires disclosure of each drug's "average wholesale cost" but does not define that term. The majority of bills also require the manufacturers to report the drug's AWP, despite the fact that AWP has never been defined in law and since 2004 most manufacturers have neither calculated nor reported an AWP for their drugs.
  • All of the bills require manufacturers to disclose the research and development costs for the drug, but often do not delve into specifics such as whether inclusion of costs associated with predecessor failed drugs may be included. Most bills also require some form of reporting of manufacturing costs, marketing/promotional costs, and profits.
  • The North Carolina bill requires the disclosures be filed with the State Insurance Commissioner, although it is not clear what authority that Commissioner has over a non-insurer drug manufacturer. The Pennsylvania bill requires disclosures be made to a newly-established Pharmaceutical Transparency Commission operating under the auspices of the State Insurance Department — that Commission would be made up of government, pharmacy, insurance and consumer representatives; would be funded by manufacturer assessments but include no manufacturer representation; and, would be empowered to determine insurance reimbursement caps for the drugs. The OR bill specifies that the manufacturer reports are to be auditable and publicly posted, while the MA bill exempts the manufacturers' reports from disclosure under state public records laws.

AWP Cases and Pricing Transparency

By the late 1990s, the majority of insurers reimbursed pharmacies for prescription drugs using the measure of AWP. AWP was not defined in any statute; was recognized in the industry as in essence a marked-up acquisition cost exclusive of any discounts; and had become an industry-recognized measure used by drug manufacturers, wholesalers, repackagers, pharmacies, and public and private insurers. The majority of state Medicaid programs based pharmacy reimbursement on AWP less a certain percentage, 10% on average.

The first AWP cases were brought in the late 1990s by whistleblowers under the federal and state false claims acts (FCA) and were limited to biologic drugs dispensed in a physician's office or clinic. Generally health care professionals are directly paid by insurers for the costs of these drugs. The whistleblowers alleged manufacturers manipulated a drug's published AWP as a marketing scheme to incentivize use of that drug by the clinicians or physicians: the higher the published AWP, the higher the payor's reimbursement rate for that drug.

When contemplating settlement of the early AWP cases, naïve state Medicaid Fraud attorneys (which, with full disclosure, included me) advocated that any settlement include transparency terms, requiring the settling manufacturer to disclose future average sales prices to the state Medicaid programs. Federal law does not mandate states use AWP as a basis for Medicaid reimbursement, so theoretically states could base Medicaid reimbursement on more accurate information directly provided by the manufacturers. We believed the states could and would adjust reimbursement rates using these new, more accurate, pricing reports.

So beginning in 2000, multiple AWP settlements incorporated requirements that the manufacturer report average sales price information to the State Medicaid program on a quarterly basis, and those reports were filed with the states.

In the years that followed, AWP litigation became a cottage industry for the states. In multiple states, contingency fee counsel filed AWP lawsuits on behalf of State Attorneys General against almost every known drug manufacturer; these lawsuits alleged that State Medicaid programs unwittingly overpaid for drugs due to their reliance on AWP-based reimbursement. When it came to drugs dispensed through pharmacies, these lawsuits frequently alleged that AWP manipulation was used to persuade pharmacists to dispense certain manufacturers' drugs over competitor products, ignoring the physicians' role in prescribing the drugs in the first place.

In those post-2000 lawsuits, manufacturers pointed out that the state Medicaid programs were not mandated to use AWP and in fact had certain sales price information in hand, directly provided by manufacturers under the prior AWP settlements. In response, the states argued that those price reports went unread, generally because they were too complicated for the state employees to understand, let alone act upon.

The AWP experience in Mississippi is illustrative. In 2006 the MS Attorney General filed an AWP lawsuit against more than 100 drug manufacturers, alleging that the state was defrauded into overpaying for thousands of drugs because the MS Medicaid reimbursement methodology largely relied upon AWP. Specifically, MS asserted that its Medicaid program staff believed that AWP was the price at which pharmacies actually purchased drugs from wholesalers, inclusive of all discounts, and was shocked to "recently" learn that was not the case.

At the time that lawsuit was filed in 2006, MS had already participated in multiple AWP lawsuits and had been receiving average sales price reports from those settling manufacturers. Yet, not only did MS Medicaid continue to use an AWP-based Medicaid reimbursement formula for six years before it filed its lawsuit, it continued to use AWP as a basis for Medicaid reimbursement for eight more years after filing that lawsuit.

Finally, MS Medicaid announced that beginning July 1, 2014 it would drop AWP and instead base Medicaid reimbursement on the average cost pharmacies paid to purchase the drugs (Average Acquisition Cost or AAC).

And that change lasted less than eight weeks. MS pharmacists revolted, later bragging that it was "the quick and effective actions" of the MS Independent Pharmacists Association that forced the state to reverse course. Effective August 21, 2014, the state abandoned AAC and reverted to its prior Medicaid reimbursement methodology using AWP; MS Medicaid notified pharmacies they could resubmit any claims paid using AAC for reprocessing under the old AWP formula. And MS continues to use AWP in its Medicaid pharmacy reimbursements.

Moral of the AWP Story

When it comes to payment for prescription drugs in the United States, the process is admittedly opaque. But in fact most state citizens do not purchase their medications directly from pharmaceutical manufacturers at a price set by that manufacturer. Most drugs are dispensed by pharmacies, or in hospitals or other facilities, or are administered by physicians; those entities obtain the drugs from wholesalers or repackagers, many utilizing the services of a Group Purchasing Organization or Pharmacy Services Administrative Organization; the entity dispensing the drugs is often reimbursed in whole or in part by a government program or by private insurer who may have utilized the services of a pharmaceutical benefit manager in setting standards for payment, including setting the individual's co-payment rates.

The saga of AWP litigation should have made clear to state legislators that getting the government's arms around drug pricing involves more than just requiring the manufacturers to report prices to some state government entity. Indeed, they may first want to ask their State Medicaid programs whether anyone in the agency reviewed the last fifteen years of sales price reports already furnished by manufacturers who settled AWP litigation, and/or inquire whether like in MS, access to that information was never considered in determining the prices their state Medicaid program paid for those drugs.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Ellyn Sternfield
Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions